These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

753 related articles for article (PubMed ID: 34860572)

  • 1. Impact of
    Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
    J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia.
    Myers GD; Verneris MR; Goy A; Maziarz RT
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33846220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
    Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
    Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
    Abramson JS; Lunning M; Palomba ML
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia.
    Zhang X; Yang J; Li J; Li W; Song D; Lu XA; Wu F; Li J; Chen D; Li X; Xu Z; Liu S; Li Z; Ying K; Lu P
    Cancer Immunol Immunother; 2022 Mar; 71(3):689-703. PubMed ID: 34365516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
    Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
    Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives.
    Mohty M; Gautier J; Malard F; Aljurf M; Bazarbachi A; Chabannon C; Kharfan-Dabaja MA; Savani BN; Huang H; Kenderian S; Nagler A; Perales MA
    Leukemia; 2019 Dec; 33(12):2767-2778. PubMed ID: 31690821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
    Scholler N; Perbost R; Locke FL; Jain MD; Turcan S; Danan C; Chang EC; Neelapu SS; Miklos DB; Jacobson CA; Lekakis LJ; Lin Y; Ghobadi A; Kim JJ; Chou J; Plaks V; Wang Z; Xue A; Mattie M; Rossi JM; Bot A; Galon J
    Nat Med; 2022 Sep; 28(9):1872-1882. PubMed ID: 36038629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level Data.
    Messori A; Chiumente M; Mengato D
    Clin Ther; 2022 Dec; 44(12):1626-1632. PubMed ID: 36503735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
    Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
    Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of aggressive B-cell lymphoma with TP53 alterations administered with CAR T-cell cocktail alone or in combination with ASCT.
    Wei J; Xiao M; Mao Z; Wang N; Cao Y; Xiao Y; Meng F; Sun W; Wang Y; Yang X; Chen L; Zhang Y; Zhu H; Zhang S; Zhang T; Zhou J; Huang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):101. PubMed ID: 35399106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.